Advances in HIV-1Vaccine Volume I
Since the human immunodeficiency virus (HIV) was identified as the causative agent of acquired immunodeficiency syndrome (AIDS), the Human Immunodeficiency Virus (HIV) represents a worldwide threat to public health and the economy. It has been estimated that 35.3 (32.2-38.8) million people were living with HIV globally at the end of 2012. HIV has two major types, HIV-1 and HIV-2, which are further divided into groups, subtypes and recombinant forms. Globally, over 90% of HIV infections belong to HIV-1 group M viruses. Despite of the successful use of highly active antiretroviral therapy, the high genetic diversity of the HIV genomehas challenged the development of drugs and vaccines. Twenty-five years of research into development of a vaccine to prevent or control HIV-1 infection doesn’t lead to available protective vaccines. The aim of this book is to provide an overview of the status of research within the HIV vaccine.
Components of the Book:
  • FRONT MATTER
  • Chapter 1
    Therapeutic HIV Vaccines: Prior Setbacks, Current Advances, and Future Prospects
  • Chapter 2
    Development of Prophylactic Vaccines against HIV-1
  • Chapter 3
    An Integrated Map of HIVGenome-Wide Variation from a Population Perspective
  • Chapter 4
    The HIV-1 Pandemic: Does the Selective Sweep in Chimpanzees Mirror Humankind’s Future?
  • Chapter 5
    HIV-1 Vaccine Immunogen Design Strategies
  • Chapter 6
    HIV Vaccine-Induced Sero-Reactivity: A Challenge for Trial Participants, Researchers, and Physicians
  • Chapter 7
    Immune Quiescence: AModel of Protection against HIV Infection
  • Chapter 8
    Immunogenicity of a Recombinant Measles HIV-1 Subtype C Vaccine
  • Chapter 9
    The HIV Glycan Shield as a Target for Broadly Neutralizing Antibodies
  • Chapter 10
    The Role of Neutralizing Antibodies in Prevention of HIV-1 Infection: What Can We Learn from the Mother-to-Child Transmission Context?
  • Chapter 11
    Identification of Broadly Neutralizing Antibody Epitopes in the HIV-1 Envelope Glycoprotein Using Evolutionary Models
  • Chapter 12
    HIV-1 Envelope Glycoprotein Signatures that Correlate with the Development of Cross-Reactive Neutralizing Activity
Readership: Clinical practitioners and scientists in HIV vaccine and immunology; immunological researchers; medical, medicinal and immunological students and those with an interest in HIV vaccine.
Christian Brander
ICREA Senior Research Professor,IrsiCaixa Institute for AIDS Research, Spain.

Dan H Barouch
Professor of Medicine at Harvard Medical School and Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, United States.

George Dickson
University Chair of Molecular Cell Biology, Royal Holloway, University of London, Egham, Department of Biological Sciences, UK.

Lucy Dorrell
Associate Professor/Honorary Consultant Physician, Nuffield Department of Clinical Medicine, University of Oxford, UK.

Ronald E Bontrop
Research Director, Biomedical Primate Research Centre, Rijswijk, Netherlands.

and more...
Copyright © 2006-2021 Scientific Research Publishing Inc. All Rights Reserved.
Top